News

Analyst Highlights Kimberly-Clark's Attractive Investment Opportunities

Analyst Highlights Kimberly-Clark's Attractive Investment Opportunities

Analyst Insights on Kimberly-Clark's Performance

Goldman Sachs analyst Bonnie Herzog has maintained a Buy rating on Kimberly-Clark Corporation (KMB), suggesting that the company's growth potential is significantly underestimated. Herzog's price forecast for KMB stock stands at $152, indicating a robust outlook for the company.

Quarterly Earnings Overview

In its recent quarterly report, Kimberly-Clark exceeded expectations with an adjusted earnings per share of $1.83, surpassing the street's estimate of $1.70. However, the company reported revenues of $4.952 billion, which were slightly below the consensus estimate of $5.048 billion. This mixed earnings report highlights areas of strength and opportunity for the company.

Management Strategies and Market Predictions

According to Herzog, the current management strategies aimed at enhancing productivity are expected to facilitate margin expansion. Analyst projections reveal that there is an underestimation of the company's ability to grow its gross margin, which should concurrently contribute to earnings per share (EPS) growth, even amid increased reinvestments.

Segment Reorganization and Its Benefits

Herzog mentions that a reorganization in Kimberly-Clark's business segments is likely to improve operational execution moving forward. This strategic change is crucial for optimizing performance and ensuring sustainable growth in a competitive market.

Investment Outlook and Market Valuation

The analyst sees a favorable risk/reward scenario for investors as Kimberly-Clark's improving fundamentals sharply contrast with its significant valuation discount compared to peers in the household and personal care (HPC) segment. This discrepancy presents an attractive entry point for potential investors looking to capitalize on the company’s growth trajectory.

Future Projections for Earnings

Looking ahead, Herzog predicts that adjusted EBIT is expected to grow in the mid-to-high teens on a constant currency basis, with adjusted EPS also projected to mirror this growth trajectory. This positive outlook is indicative of the company's resilience and ability to navigate market challenges effectively.

Fourth Quarter Forecasts

For the fourth quarter, organic sales growth is anticipated to be around 4%, particularly at the mid-point, which slightly trails Goldman Sachs's estimate of 5.0%. The projected all-in EPS is forecasted to be approximately $1.46, with a range between $1.33 to $1.60. This reflects an impressive constant currency growth of 15% to 19%, reaffirming the company's strong operational performance.

Current Stock Performance

As of the latest market check, KMB shares are trading down by 4.30%, settling at $138.01. This dip in stock price could present an opportunity for investors looking for a buying opportunity within a historically strong company.

Frequently Asked Questions

What is the current price forecast for Kimberly-Clark stock?

Goldman Sachs analyst Bonnie Herzog has set a price forecast of $152 for Kimberly-Clark (KMB) stock.

How did Kimberly-Clark perform in the latest earnings report?

Kimberly-Clark reported adjusted earnings per share of $1.83, exceeding expectations, while revenues were $4.952 billion, missing the analyst consensus.

What are the growth projections for Kimberly-Clark?

The analyst projects strong growth for both adjusted EBIT and EPS in the mid-to-high teens on a constant currency basis.

Is Kimberly-Clark a good investment opportunity?

Analysts suggest that Kimberly-Clark offers an attractive entry point due to its improving fundamentals and undervalued stock compared to peers.

What is the outlook for Kimberly-Clark's fourth quarter?

The company anticipates organic sales growth of about 4% in the fourth quarter, with projected EPS in the range of $1.33 to $1.60.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Hyundai and Texas Children's Boost Child Safety in Houston

Updated Category News Views 6

A Meaningful Partnership for Safer Houston Roads There's a good feeling about corporations genuinely pitching in for community welfare, and Hyundai teaming up with Texas Children's Hospital to boost child passenger safety around Houston is exactly that. Pairing philanthropy with safety is more than just a business move—it's a testament to human decency. With a $25,000...

Continue Reading
Viedoc and Bioforum Unite: Clinical Data Innovation

Updated Category News Views 19

Revamping Clinical Trials with Data Integration It doesn't take a Wall Street wizard to understand that in today's research game, having data is only half the battle—using it effectively is where the rubber meets the road. Enter Viedoc and Bioforum, two names that are well-acquainted with the grind of the clinical research world. These seasoned pros have joined forces,...

Continue Reading
Torchy's Tacos Reintroduces Nookies: Fan Favorite Returns

Updated Category News Views 34

A Sweet Return to the Menu In the wild world of fast-casual dining, bringing back a beloved menu item is like striking gold. Torchy's Tacos is doing just that by reintroducing their legendary Nookies—fried chocolate chip cookie dough bites that have been a crowd favorite since 2008. After a two-year hiatus, these treats are back, complete with a cinnamon-sugar twist to...

Continue Reading
Static Media Acquires CarScoops to Boost Auto Reach

Updated Category News Views 24

Static Media's Latest Move in the Automotive Arena The digital media landscape keeps morphing, and Static Media just decided to crank up the gears a notch by snapping up CarScoops.com. For those with an eye on the automotive field, it's the kind of play that could shift the tides. Static Media, already a heavyweight with brands like Jalopnik and SlashGear under its belt,...

Continue Reading
Wabi's $1.25B Valuation: A New Era for AI?

Updated Category News Views 71

A Major Milestone for Wabi Well, here we go—Wabi, the brainchild of Eugenia Kuyda, is stirring the pot with a massive $55 million funding round, pulling its valuation up to a hefty $1.25 billion. If you're raising eyebrows at that price tag, you’re not alone. It's a big number riding on an even bigger idea: that AI isn't just for solitary chats anymore, but for...

Continue Reading
Cyclists and Trains: A New Chapter in Urban Travel

Updated Category News Views 23

Rolling Without Engines: LA to SD Picture this: over 75 cyclists and their compact, foldable steeds embarking on a train journey from Los Angeles to the sun-drenched streets of San Diego. In an era where travel is often synonymous with congestion and pollution, this collaboration between Amtrak's Pacific Surfliner and Brompton Bicycle was like a breath of fresh sea air....

Continue Reading
Ascletis' ASC30 Achieves Significant HbA1c Reductions

Updated Category News Views 73

When you dive into the world of biopharma, you never quite know what's going to grab your attention next. Today, it's Ascletis Pharma's (HKEX: 1672) GLP-1 receptor agonist, ASC30, that's piqued my interest. It just wrapped up a U.S. Phase II study with a bang, showing off with some impressive results for type 2 diabetes treatment. This ain't no half-hearted...

Continue Reading
Florida 500 Honors Influential Health Leaders of 2026

Updated Category News Views 56

Florida 500: Recognizing Impactful Leaders When it comes to shaking up the healthcare scene in Florida, John Couris and his crew are hardly treading water. Once again, Couris is rubbing elbows with the state's influential set, nabbing a spot on Florida Trend's 2026 "Florida 500" list. If you don't know, that's six years in a row. Those who've walked the grueling paths in...

Continue Reading
Nikon Unveils Game-Changing Zoom Lens for Pros

Updated Category News Views 35

Nikon Raises the Bar with New Pro Zoom Lens Well, Nikon's done it again, folks. They've dropped the NIKKOR Z 120-300mm f/2.8 TC VR S lens, and it looks like they're giving photographers something to drool over. Now, before you start rolling your eyes, this isn't just another shiny gadget. This bad boy is lighter and faster than anything Nikon's thrown at us before, and it...

Continue Reading
InventHelp's BLU MESH: A Breath of Fresh and Bug-Free Air

Updated Category News Views 16

Breathing Fresh Air Without the Buzz Here's a fresh spin on driving with the windows down: avoiding bug invasions. We’ve all experienced it—the unexpected slap on the arm or that annoying buzz in your ear just as you're drifting into a long podcast. Thanks to an inventor from East Stroudsburg, Pa., there's an idea on the table for a vehicular add-on that might just...

Continue Reading

Top 5 Most Recently Viewed Articles

Cintas Corporation Exceeds Expectations and Adjusts Outlook

Updated Category News Views 132

Cintas Corporation's Strong First Quarter Performance Cintas Corporation (NASDAQ: CTAS) recently surprised the market with its stellar first-quarter sales figures, which exceeded expectations and showcased a robust increase in profit margins. This strong performance has set the tone for optimistic forecasts moving forward. Impressive Earnings and Sales Growth The company...

Continue Reading
Streamlined AI Video Analytics for Public Safety Unveiled

Updated Category News Views 28

AI Without the Headache Alright folks, IREX is shaking things up, and not in the usual iterative, bit-by-bit tech progression way. StreamVLM™ has been rolled out as the world's first vision-language model (VLM) analytics engine tailored for the public safety sector—specifically, for cloud platforms. I’ve been around the block enough times to spot a significant shift...

Continue Reading
All Hands and Hearts Mobilizes for Relief Efforts in California

Updated Category News Views 245

All Hands and Hearts Steps Up in Response to Wildfires In light of the recent devastating wildfires, All Hands and Hearts (AHAH) has mobilized its team and resources to provide critical disaster relief efforts in the affected areas. Known for its community-driven and volunteer-supported approach, AHAH is drawing on two decades of experience in disaster response. This...

Continue Reading
Realty Income Celebrates 664 Consecutive Monthly Dividends

Updated Category News Views 178

Realty Income Declares 664th Monthly Dividend Realty Income Corporation, also known as The Monthly Dividend Company, recently announced the declaration of its remarkable 664th consecutive common stock monthly dividend. Investors can look forward to receiving a dividend of $0.2695 per share, which translates to an annualized figure of $3.234 per share. This dividend is set...

Continue Reading
Innovative Clinical Trial Aims to Revolutionize Myeloid Cancer Care

Updated Category News Views 167

Innovative Clinical Trial Aims to Revolutionize Myeloid Cancer Care The National Institutes of Health (NIH) has recently initiated a groundbreaking clinical trial designed to explore precision medicine treatments for myeloid cancers, particularly acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). This initiative focuses on tailored treatment combinations...

Continue Reading